home > about us > investors
Mesophotonics has raised two rounds of funding totalling £8.3m from top tier venture capital funds and corporate investors.
Auriga Partners is a French independent early stage VC fund.
Auriga focuses on investments in high-potential, innovative
start-ups in the areas of life sciences and information technology,
mainly in Europe. To date Auriga manages about €200 million
funds, split between three funds: European Medical Ventures,
Auriga Ventures I and Auriga Ventures II.
For further information please refer to www.aurigapartners.com
BTG finds, develops and commercialises emerging technologies
in the life and physical sciences. These innovations are
protected by a strong portfolio of intellectual property that
BTG develops and enhances. BTG then captures the value in these
technologies through licensing and venturing activities.
From the origins of its business in 1949, BTG has commercialised
major innovations such as Magnetic Resonance Imaging (MRI),
recombinant factor IX blood-clotting protein, Campath® (alemtuzumab)
and Multilevel Cell (MLC) memory. BTG is on the London Stock
Exchange under the symbol "BGC" and operates from
offices in London and Philadelphia, with representation in Tokyo.
BTG operates through wholly owned subsidiaries, BTG International
Ltd and BTG International Inc in the UK and USA, respectively.
Further information on BTG can be found at www.btgplc.com
NIF Ventures Co Ltd
NIF Ventures Co Ltd is the venture capital arm of the Daiwa
Securities Group of Japan and manages approximately $1 billion
in venture capital funds. NIF has funded over 1,500 companies
and assisted over 450 companies to exit since its foundation
in 1982. Its primary focus is in information and communications
technologies and life science VC investments. With offices in
Japan, Taiwan, Singapore, and the United States, NIF offers
Further information on NIF can be found at www.nifsmbc.co.jp
Quester is one of the UK's leading independent venture capital
groups specialising in the provision of finance and management
support for growth companies at all stages of their life. Quester's
focus is on early stage investments in information and communication
technology, healthcare and life science companies. With its
first rate track record, Quester has earned a reputation as
one of the best UK based sources of venture capital. The Quester
investment team manages approximately £300 million on
behalf of major institutional investors, leading UK universities,
and five quoted venture capital trusts.
For further information please refer to www.quester.co.uk